Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective - 16/01/22
pages | 13 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Immunotherapy such as immune checkpoint blockade and adoptive cell transfer has revolutionized cancer treatment. |
• | Intratumoral heterogeneity is one of the main challenges in cancer immunotherapy. |
• | Single-cell RNA sequencing can identify new targets for immunotherapy that bulk genomics cannot fully capture. |
Keywords : ScRNA-seq, Immunotherapy, Cancer, Immune checkpoints
Plan
Vol 146
Article 112558- février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?